Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data validation
1.4 Forecast parameters
1.5 Data sources
1.5.1 Primary
1.5.2 Secondary
1.5.2.1 Paid sources
1.5.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing incidence of pompe disease
3.2.1.2 Expanding R&D efforts
3.2.1.3 Growing regulatory support
3.2.1.4 Increasing emphasis on early diagnosis advancement
3.2.1.5 Favorable reimbursement policies
3.2.2 Industry pitfalls & challenges
3.2.2.1 Limited treatment options
3.2.2.2 High treatment costs
3.3 Growth potential analysis
3.4 Pipeline assessment
3.5 Reimbursement scenario
3.6 Regulatory landscape
3.7 Porter’s analysis
3.7.1 Supplier power
3.7.2 Buyer power
3.7.3 Threat of new entrants
3.7.4 Threat of substitutes
3.7.5 Industry rivalry
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Enzyme replacement therapy (ERT)
5.3 Supportive care
Chapter 6 Market Estimates and Forecast, By Disease Type, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Infantile
6.3 Juvenile
Chapter 7 Market Estimates and Forecast, By Therapy, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Monotherapy
7.3 Combination therapy
Chapter 8 Market Estimates and Forecast, By End-User, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Infusion centers
8.4 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Abeona Therapeutics Inc.
10.2 Amicus Therapeutics, Inc.
10.3 Aro Biotherapeutics Company
10.4 Audentes Therapeutics (Astellas Pharma Inc.)
10.5 Bayer AG
10.6 F. Hoffmann-La Roche Ltd.
10.7 Genethon
10.8 Maze Therapeutics
10.9 M6P Therapeutics
10.10 Oxyrane
10.11 Sanofi
10.12 Valerion Therapeutics
